A Multiple Ascending Dose Study of MEDI7247 in Participants with Selected Relapsed/Refractory Hematological Malignancies

Exclusion Criteria

• 1. Received cytotoxic chemotherapy within 21 days (or 42 days for nitrosureas or mitomycin C) prior to the first scheduled dose of MEDI7247.
• 2. Received major surgery (as defined by the Investigator), radiotherapy, or immunotherapy (including immune checkpoint inhibitors and adoptive cellular therapy such as autologous or donor natural killer (NK) cell or T lymphocyte infusions (e.g. CAR -T cells)) within 28 days of the first scheduled dose of MEDI7247.
• 3. Received an investigational drug within 14 days of the first scheduled dose of MEDI7247 or not recovered from associated toxicities.
• 4. Participants who have previously received an autologous stem cell transplant (SCT), are excluded if less than 120 days have elapsed from the time of transplant or the participant has not recovered from transplant-associated toxicities prior to the first scheduled dose of MEDI7247.
• 5. History of liver cirrhosis, liver fibrosis or prior liver irradiation regardless of the time interval (not including total body irradiation administered during allogeneic SCT).
• 6. Failure to recover from all prior treatment-related non-hematological toxicities to <= Grade 1 prior to the first scheduled dose of MEDI7247 (except for alopecia and neuropathy).
• 7. Participants at risk of non-disease related major bleeding (eg, recent gastrointestinal hemorrhage or neurosurgery, within previous 21 days).
• 8. Current severe active systemic disease including active concurrent malignancy
• 9. Central nervous system (CNS) disease that is untreated, symptomatic, or requires therapy to control symptoms.
• 10. Active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections at the time of screening.